Journal of Osteoporosis / 2016 / Article / Fig 2

Review Article

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges

Figure 2

The first in vivo study to test anti-sclerostin antibodies for increasing bone mass involved a rodent model of postmenopausal osteoporosis. Ovariectomised (OVX) rats were treated with 25 mg/kg of sclerostin antibody twice weekly for 5 weeks while sham-operated controls (Sham) were treated with PBS. Treatment with sclerostin antibody reportedly restored trabecular bone volume and bone mineral density (BMD) to comparable levels observed in sham-operated animals. Trabecular volumetric BMD = Tb. vBMD; median trabecular bone volume = Tb. BV/TV. versus OVX + vehicle. Reproduced with permission from Li et al. [50].